Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. Pipe SW, et al. Among authors: kenet g. Blood. 2024 Apr 4;143(14):1355-1364. doi: 10.1182/blood.2023021832. Blood. 2024. PMID: 38127586 Free PMC article. Clinical Trial.
Factor VIII products and inhibitor development in severe hemophilia A.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Gouw SC, et al. Among authors: kenet g. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024. N Engl J Med. 2013. PMID: 23323899 Free article.
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee. Kreuz W, et al. Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23. Haemophilia. 2016. PMID: 26202305 Free article.
The prognostic value of blood cellular indices in pulmonary embolism.
Siddiqui F, Tafur A, Hussain M, García-Ortega A, Darki A, Fareed J, Jiménez D, Bikdeli B, Galeano-Valle F, Fernández-Reyes JL, Pérez-Pinar M, Monreal M; RIETE Investigators. Siddiqui F, et al. Am J Hematol. 2024 May 30. doi: 10.1002/ajh.27379. Online ahead of print. Am J Hematol. 2024. PMID: 38816957
Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.
Young G, Pipe SW, Kenet G, Oldenburg J, Safavi M, Czirok T, Nissen F, Mahlangu J. Young G, et al. Among authors: kenet g. Res Pract Thromb Haemost. 2024 Apr 18;8(4):102415. doi: 10.1016/j.rpth.2024.102415. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 38812987 Free PMC article. Review.
Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism.
Gabara C, Aibar J, Nishimoto Y, Yamashita Y, Prandoni P, Barnes GD, Bikdeli B, Jiménez D, Demelo-Rodríguez P, Peris ML, Nguyen ST, Monreal M; Registro Informatizado Enfermedad Trombo Embólica Investigators. Gabara C, et al. J Thromb Haemost. 2024 May 16:S1538-7836(24)00289-7. doi: 10.1016/j.jtha.2024.05.007. Online ahead of print. J Thromb Haemost. 2024. PMID: 38762019
334 results